Novavax Inc. Stock Advances 6.1%, Outperforms Peers

Dow Jones01-03

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of Novavax Inc. advanced 6.1% to $7.13 on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index remaining mostly unchanged at 23,235.63 and the Dow Jones Industrial Average rising 0.7% to 48,382.39.

Novavax Inc. closed 38.3% below its 52-week high of $11.55, which the company achieved on January 7th.

The stock outperformed some of its peers, as Johnson & Johnson rose 0.2% to $207.35, Pfizer Inc. rose 1.1% to $25.18, and Merck & Co. Inc. rose 1.13% to $106.45.

Trading volume totaled 3.9 million, compared to the 50-day average of 3.6 million.

Data source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

January 02, 2026 16:34 ET (21:34 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment